Results 61 to 70 of about 7,834 (208)

Nab-paclitaxel for the treatment of triple-negative breast cancer: Rationale, clinical data and future perspectives [PDF]

, 2016
Triple-negative breast cancer (TNBC) accounts for ∼10-20% of breast cancers and is associated with relatively poor prognosis, earlier disease recurrence and higher number of visceral metastases.
ARPINO, GRAZIA, DE PLACIDO, SABINO, GIULIANO, MARIO, SCHETTINI, FRANCESCO   +3 more
core   +1 more source

SF3B1 hotspot mutations confer sensitivity to PARP inhibition by eliciting a defective replication stress response. [PDF]

, 2023
SF3B1 hotspot mutations are associated with a poor prognosis in several tumor types and lead to global disruption of canonical splicing. Through synthetic lethal drug screens, we identify that SF3B1 mutant (SF3B1MUT) cells are selectively sensitive to ...
Allen, M, Alsafadi, S, Barker, HE, Barlow, S, Bland, P, Broderick, R, Choudhary, JS, Coupland, SE, Curnow, L, Gazinska, P, Gulati, A, Guppy, N, Haider, S, Hedayat, S, Houy, A, John, MB, Kalirai, H, Lord, CJ, Mavrommati, I, Muirhead, G, Nash, S, Natrajan, R, Niedzwiedz, W, Nieminuszczy, J, Noor, F, Oldreive, C, Peck, B, Pemberton, HN, Pettit, S, Pratt, G, Ravindran, N, Read, A, Roxanis, I, Saville, H, Stankovic, T, Stern, M-H, Wai, PT, Wright, J, Yu, L   +38 more
core   +2 more sources

Network divergence analysis identifies adaptive gene modules and two orthogonal vulnerability axes in pancreatic cancer

Molecular Oncology, EarlyView.
Tumors contain diverse cellular states whose behavior is shaped by context‐dependent gene coordination. By comparing gene–gene relationships across biological contexts, we identify adaptive transcriptional modules that reorganize into distinct vulnerability axes.
Brian Nelson, Lyanne Delgado‐Coka, Natalia Marchenko, Luisa F. Escobar‐Hoyos, Kenneth R. Shroyer, Alisa Yurovsky, Trey Ideker, Gábor Balázsi, Thomas MacCarthy, Scott Powers   +9 more
wiley   +1 more source

PARP inhibitors in the treatment of metastatic breast cancer patients with germline BRCA1/2 mutations. Experience of treatment with talazoparib in clinical practice

Медицинский совет, 2020
Germline BRCA1/2 mutations account for about 10% of all breast cancer. BRCA1/2 proteins are involved in homologous recombination - DNA double-strand break repair mechanism.
M. A. Frolova, E. V. Glazkova, M. B. Stenina   +2 more
doaj   +1 more source

Hippo pathway at the crossroads of stemness and therapeutic resistance in breast cancer

Molecular Oncology, EarlyView.
Dysregulation of the Hippo pathway drives nuclear accumulation of YAP/TAZ, activating stemness‐related transcriptional programs that sustain breast cancer stemness and fuel therapeutic resistance across subtypes, underscoring Hippo signaling as a targetable vulnerability. Figure created and edited with BioRender.com.
Giulia Schiavoni, Antonella Palmese, Stefano Scalera, Laura Cipriani, Davide Mascolo, Patrizia Vici, Teresa Arcuri, Lorena Filomeno, Eriseld Krasniqi, Giovanni Blandino, Giulia Bon, Marcello Maugeri‐Saccà   +11 more
wiley   +1 more source

The Combination of Radiation with PARP Inhibition Enhances Senescence and Sensitivity to the Senolytic, Navitoclax, in Triple Negative Breast Tumor Cells

Biomedicines, 2023
Despite significant advances in the treatment of triple-negative breast cancer, this disease continues to pose a clinical challenge, with many patients ultimately suffering from relapse.
Abrar Softah, Moureq R. Alotaibi, Ali R. Alhoshani, Tareq Saleh, Khalid Alhazzani, Mashal M. Almutairi, Raed AlRowis, Samiyah Alshehri, Norah A. Albekairy, Hisashi Harada, Rowan Boyd, Eesha Chakraborty, David A. Gewirtz, Homood M. As Sobeai   +13 more
doaj   +1 more source

PARP inhibitors for BRCA1/2-mutated and sporadic ovarian cancer: current practice and future directions [PDF]

, 2016
Poly(ADP-ribose) polymerase (PARP) inhibitors cause targeted tumour cell death in homologous recombination (HR)-deficient cancers, including BRCA-mutated tumours, by exploiting synthetic lethality.
Konecny, G, Kristeleit, RS
core  

Endocrine resistance in hormone receptor positive breast cancer–from mechanism to therapy [PDF]

, 2019
The importance and role of the estrogen receptor (ER) pathway has been well-documented in both breast cancer (BC) development and progression. The treatment of choice in women with metastatic breast cancer (MBC) is classically divided into a variety of ...
Giamas, G., Giamas, G., Murphy, J.J., Murphy, J.J., Rani, A., Rani, A., Stebbing, J., Stebbing, J.   +7 more
core   +3 more sources

PARP inhibitors induce a senescence phenotype in non‐small cell lung carcinoma cell lines

FEBS Open Bio, EarlyView.
Talazoparib is the most potent inducer of senescence among different PARP1 inhibitors in human NSCLC cells. In the absence of PARP, no senescence phenotype was observed, demonstrating that PARP1 is necessary for the induction of senescence by this inhibitor.
Camille Huart, Manon Van den Abbeel, Christoph Schifflers, Karim Bouhjar, Andrea Scarmelotto, Alexis Khelfi, Anne‐Catherine Wera, Carine Michiels   +7 more
wiley   +1 more source

Combination Immunotherapy as a Promising Strategy to Overcome Immunotherapy Resistance: From Emergence to Next‐Generation Approaches

Advanced Science, EarlyView.
This review examines emerging combination immunotherapy strategies tailored to distinct tumor microenvironments and highlights next‐generation biomarkers that guide response prediction and treatment personalization. It integrates lessons from unsuccessful trials, addresses toxicity challenges, and outlines approaches for early biomarker discovery and ...
Asmita Pandey, Sudhir Kumar Rai, Li Ma, Lauren Higa, Vedbar Khadka, Hua Yang, Youping Deng   +6 more
wiley   +1 more source